Molecular Theranostics
Ohio, US · Founded 2014 · 1 known investors
Find your way into Molecular Theranostics
MT develops cancer-specific molecular imaging agents (probes) targeting a common oncoprotein in the tumor microenvironment, intended for use with imaging modalities such as CT, PET, MRI, SPECT and ultrasound. The agents are aimed at early detection and diagnosis of aggressive tumors across multiple cancer types for clinical cancer management.
Founders & leadership
AC
Audrey Carballo
Investors · 1
Competitors · 2
by search overlapUclahealth3 shared keywordsUCLA Health is a major academic health system providing patient care across five hospitals and 290 clinics in Southern California and the Central Coast, alongside research and medical education. The organization conducts pioneering research in oncology, transplantation, neurosurgery, and other specialties, having contributed to the development of numerous FDA-approved treatments.
Mtem3 shared keywordsMolecular Templates, Inc. was a clinical-stage biopharmaceutical company formerly based in Austin, TX. The company is no longer operating.
Companies competing with Molecular Theranostics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $265.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $2.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $249.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Molecular Theranostics do?
- MT develops cancer-specific molecular imaging agents (probes) targeting a common oncoprotein in the tumor microenvironment, intended for use with imaging modalities such as CT, PET, MRI, SPECT and ultrasound. The agents are aimed at early detection and diagnosis of aggressive tumors across multiple cancer types for clinical cancer management.
- Who are Molecular Theranostics's investors?
- Molecular Theranostics's investors include CWRU Technology Ventures.
- Where is Molecular Theranostics headquartered?
- Molecular Theranostics is headquartered in Ohio, US.